Список проголосовавших за комментарий " On The Wires<ul><li>Daxor Corporation, (<strong>DXR</strong>) announces a new randomized controlled trial analysis presented in at the Society of Critical Care meeting this month confirming a markedly lower ICU mortality rate with fluid and red blood cell management individualized according to direct blood volume analysis compared with conventional care using pulmonary artery catheter alone.</li><li>Immunomedics (<strong>IMMU</strong>) filed an investor presentation with the SEC titled «Setting the Record Straight: Immunomedics is Acting in the Best Interests of All Stockholders to Maximize Near-Term Value.»</li><li>Malvern Bancorp, Inc. (<strong>MLVF</strong>), appointed Alexander Opiela III, COO replacing Karen Walter. Prior to joining Malvern, Alex served as the Senior Vice President, Chief Risk and Compliance Officer, for Royal Bank America.</li><li>PharmaCyte (<strong>PMCB</strong>) has retained Facet Life Sciences to guide PharmaCyte through its pancreatic cancer therapy development lifecycle with the FDA. Facet has been working with PharmaCyte and Translational Drug Development (TD2) since September 2016 and was instrumental in expediting its pre-IND meeting with the FDA.</li></ul>"